Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Non-Current Liabilities (2017 - 2025)

Historic Total Non-Current Liabilities for Corcept Therapeutics (CORT) over the last 12 years, with Q3 2025 value amounting to $177.6 million.

  • Corcept Therapeutics' Total Non-Current Liabilities rose 3394.15% to $177.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.6 million, marking a year-over-year increase of 3394.15%. This contributed to the annual value of $146.9 million for FY2024, which is 4054.83% up from last year.
  • Per Corcept Therapeutics' latest filing, its Total Non-Current Liabilities stood at $177.6 million for Q3 2025, which was up 3394.15% from $150.3 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Total Non-Current Liabilities high stood at $177.6 million for Q3 2025, and its period low was $40.6 million during Q1 2021.
  • For the 5-year period, Corcept Therapeutics' Total Non-Current Liabilities averaged around $93.1 million, with its median value being $93.1 million (2023).
  • In the last 5 years, Corcept Therapeutics' Total Non-Current Liabilities tumbled by 94.59% in 2021 and then surged by 12965.44% in 2023.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Total Non-Current Liabilities stood at $47.5 million in 2021, then surged by 52.48% to $72.5 million in 2022, then soared by 44.16% to $104.5 million in 2023, then soared by 40.55% to $146.9 million in 2024, then rose by 20.9% to $177.6 million in 2025.
  • Its Total Non-Current Liabilities stands at $177.6 million for Q3 2025, versus $150.3 million for Q2 2025 and $148.9 million for Q1 2025.